natgillin/translations-raw huggingface dataset:
In a particular embodiment, the other therapeutic agent is an agent for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time, da je daljnje terapijsko sredstvo sredstvo za profilaksu i/ili liječenje upalnih stanja i/ili poremećaja koje uključuju degradaciju hrskavice i/ili poremećaj homeostaze hrskavice.
The compound of Claim 1 wherein R1 is dimethylaminomethyl, R2 is hydrogen, R3 is fluoro, and R4 is fluoro or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R' je dimetilaminometil, R je vodik, R* je fluor, a R* je fluor, ili njegova farmaceutski prihvatljiva gol.
System according to claims 1 and 2, wherein the washing fluid is water and said loadbearing frame is combined with at least one compartment (17) hosting equipments for supplying and distributing pressurized water towards the garments, loading and distributing detergent, heating water, evacuating the washing water towards the drain of the plumbing fixture, as well as a hot air generator for drying and in case ironing garments, and control instruments. 
Sustav u skladu s patentnim zahtjevima 1 i 2, naznačen time što je fluid za pranje voda, a navedeni nosivi okvir je u kombinaciji s najmanje jednim pregratkom (17) koji sadrži opremu za dovođenje 1 raspodjelu stlačene vode prema odjeći, punjenje i raspodjelu deterdženta, grijanje vode, izvlačenje vode za pranje prema ispustu sanitarne opreme, kao i generator vrućeg zraka, namijenjen sušenju i eventualnom glačanju odjeće, te upravljačke instrumente.
Preparation of Mosher's ester derivatives 
Priprema derivata Mosher-ovog estera
A method of preparing a compound of formula (II): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
Crslons ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, spojem formule (9):
The method according to claim 15, wherein the cancer is selected from multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma. 
uporabu u liječenju karcinoma u slučaju gdje je karcinom izabran iz skupine višestrukog mieloma, mieloproliferativnih poremećaja, karcinoma endometrija, karcinoma prostate, karcinoma mjehura, karcinoma pluća, karcinoma jajnika, karcinoma dojke, karcinoma želuca, karcinoma kolorektala i karcinoma usne skvamozne stanice; ili
The antibody of any one of claims 1-4, or 6 for use in treating or preventing Alzheimer's Disease. 
Antitijelo temeljem bilo kojeg od zahtjeva 1-4, ili 6 za upotrebu u liječenju ili sprječavanju Alzheimerove bolesti.
A method according to any of numbered embodiments 1 to 4, wherein the ratio of the diameter of the last rotor to the diameter of the first rotor is from 1.1:1 to 1.5:1. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je odnos promjera zadnjeg rotora prema promjeru prvog rotora od 1,1:1 do 1,5:1.
Propulsion system according to claim 1, said first rotary assembly comprising an upper flange and a lower flange connected to each other by rods. 
Pogonski sistem prema jednom od patentnih zahtjeva 1 do 9, pri čemu prvi sklop (400) sadrži gornju prirubnicu (406) i donju prirubnicu (408) koje su međusobno povezane šipkama (406).
the Crystal Violet is approximately 80% pure or greater. 
Crystal Violet je približno 80% čista 1li više; i antimikrobno sredstvo je Proclin 300.
ii) wherein the slurry further comprises water 20% - 80% by weight of the weight of the dry matter; and 
i ii) pri čemu kaša nadalje sadrži vodu 20% - 80 masenih % mase suhe tvari; i
The method according to claim 7 or 8, further comprising connecting one of the at least two electric meters before disconnecting another electric meter, in order to achieve a seamless switch. 
Postupak u skladu s patentnim zahtjevom 7 ili 8, naznačen time što dodatno uključuje spajanje jednog od najmanje dva brojila električne energije (103) prije otpajanja drugog brojila električne energije, kako bi se postiglo neprekinuto preklapanje.
a conductive housing including a first end, a second end, and a cavity; 
- < provodno kućište s jednim 1 drugim krajem te šupljinom;
and wherein Re and Rd are independently hydrogen or an organic residue selected from the group consisting of substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy or alkoxycarbonyl; or 
Formula (I) gdje su R* i R" nezavisno vodik ili organski ostatak izabran iz grupe koju čine supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi ili alkoksikarbonil; ili
storing a context variable of the first slice segment if it is allowed to include a dependent slice segment in the picture and the current maximum coding unit is at the end of the first slice segment; 
entropijsko dekodiranje elemenata sintakse trenutne najveće jedinice kodiranja (LCU) u prvom segmentu odsječka trenutne slike;
The method according to any of claims 1 to 3, wherein the endocannabinoid-degrading enzyme is selected from the group consisting of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se enzim koji razgrađuje endokanabinoide bira iz skupine koju čine hidrolaza amida masne kiseline (FAAH) i monoacilglicerol-lipaza (MAGI).
in said nitric oxide donor group, X1 is absent or -0-; X2 is absent or (C1-C20)alkylene; X3 is -NO or -ONO2; and said alkylene is optionally substituted by one or more -ONO2 groups. 
u navedenoj skupini koja je donor dušikovog monoksida, X1 je odsutan ili je -O-; X2 je odsutan ili je -(C1-C20)alkilen; X3 je -NO ili -ONO2; i navedeni alkilen je po potrebi supstituiran s jednom ili više -ONO2 skupina.
Process of preparation of a conjugate according to anyone of claims 17 to 20 comprising the step where a compound of formula (I) as defined in claim 1 in which T comprises a sulfide, disulfide or thiol group, or a precursor thereof, is reacted with a cell binding agent comprising a function reactive towards disulfide or thiol so that the compound and the cell binding agent are linked together via a covalent bond. 
Postupak dobivanja konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što uključuje korak u kojem spoj u skladu s patentnim zahtjevom 1 koji sadrži sulfidnu, disulfidnu ili tiolnu skupinu, ili njegov preteča, reagira sa sredstvom za vezanje na stanicu, koje sadrži funkcionalnu skupinu reaktivnu prema disulfidu ili tiolu, tako da se spoj i sredstvo za vezanje na stanicu poveže zajedno preko sulfidne ili disulfidne veze.
A rodent comprising at an endogenous MHC II gene locus a first nucleotide sequence encoding a chimeric human/rodent MHC II a polypeptide and a second nucleotide sequence encoding a chimeric human/rodent MHC II B polypeptide, wherein a human portion of the chimeric human/rodent MHC II a polypeptide comprises a human MHC II a extracellular domain and a human portion of the chimeric human/rodent MHC II B polypeptide comprises a human MHC II B extracellular domain, and wherein the chimeric human/rodent MHC II a and MHC II B polypeptides form a functional MHC II complex on a surface of a cell of the rodent. 
Glodavac koji na endogenom lokusu a gena glavnog sustava tkivne podudarnosti II (MHC II) ima nukleotidni slijed koji kodira kimerni MHC II a polipeptid čovjeka/glodavca 1/ili na endogenom lokusu f3 gena glavnog sustava tkivne podudarnosti HI (MHC II) ima nukleotidni slijed koji kodira kimerni MHC II f polipeptid čovjeka/glodavca, pri čemu ljudski dio kimernog MHC II a polipeptida čovjeka/glodavca obuhvaća humane MHC II al i 02 domene iili ljudski dio kimernog MHC II fB polipeptida obuhvaća humane MHC II 31 1 82 domene i pri čemu glodavac ima funkcionalnu ekspresiju kimernog MHC II kompleksa na površini stanice glodavca.
Where delivery is via transdermal forms, administration is continuous. 
Kada je unos u transdermalnim oblicima, primjena je kontinuirana.
Ecteinascidin 743, also known as ET743 or ecteinascidin 743 is particularly preferred. 
Ekteinascidin 743, također poznat kao ET743 ili ekteinascidin 743 posebno poželjan.
An anti-191P4D12 antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising three complementarity determining regions (CDRs) comprising the amino acid sequences of the three CDRs as set forth in SEQ ID NO:7 and a light chain variable region comprising three CDRs comprising the amino acid sequences of the three CDRs as set forth in SEQ ID NO:8. The antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises amino acid residue 20 to amino acid residue 136 of SEQ ID NO: 7 and the light chain variable region comprises amino acid residue 23 to amino acid residue 130 of SEQ ID NO: 8. 
Konjugat antitijela i lijeka koji sadrži anti-191P4D12 antitijelo ili fragment istog koji veže antigen, gdje antitijelo ili fragment istog sadrži varijabilnu regiju teškog lanca koja se sastoji od ostatka amino kiseline 20 do ostatka amino kiseline 136 sekvence SEQ ID NO: 7 te varijabilnu regiju lakog lanca koja se sastoji od ostatka amino kiseline 23 do ostatka amino kiseline 130 sekvence SEQ ID NO: 8, te pri čemu je antitijelo ili fragment istog konjugiran na monometil auristatin E (MMAE).
The reaction mixture was stirred for 15 min at room temperature and the resulting solution was added slowly (dropwise) to an icecold solution (0° C.) of indole (8.4 g, 71.7 mmol) in dry DMF (180 mL) under Ar. 
Reakcijska smjesa je miješana 15 minuta na sobnoj temperaturi i rezultirajuća otopina je dodana, polako (kap po kap) ledeno hladnoj otopini (0 stupnjeva C) indola (8,4 g, 71,7 mmol) 1 suhog DMF (180 mL) pod Ar.
A device comprising the sensor as defined in any of claims 10-11, and an electronic instrument (7) for receiving, collecting, storing, processing and/or transmitting data from said sensor. 
12. Uređaj koji sadrži senzor (1) koji je definiran u zahtjevu 8, sadrži 1 elektronički instrument (14) za primanje, skupljanje, spremanje 1 7 ili odašiljanje podataka iz senzora.
for a compound of Formula I wherein R2 is NRbRc and Rb is H, reacting a corresponding compound of formula II with a compound having the formula O═C═N—Rc; or 
(b) za spoj Formule I, gdje je R* NR"R", a R? je H, reakciji odgovarajućeg spoja Formule II sa spojem formule O=C=N-R'; ili
Alternatively, or in addition, another component could be added to the system that would allow adjustment of air pressure from compressor 50 (e.g. some type of pressure control device at or after the outlet from compressor 50). 
Alternativno, ili dodatno, neka druga komponenta se može dodati sustavu koja će omogućiti podešavanje tlaka zraka iz kompresora 50 (na primjer neka vrsta regulatora tlaka na ili poslije izlaza iz kompresora 50).
generating transformation coefficients of at least one transformation unit in the coding unit of the image, based on the predictor and the image; and 
Uređaj za kodiranje slike, te uređaj sadrži: memoriju koja pohranjuje tok bitova; i najmanje jedan procesor konfiguriran za:
The immunogenic composition of paragraph 62 or 63 wherein the at least two further bacterial saccharide conjugates comprises N . meningitidis serogroup C capsular saccharide (MenC) conjugate. 
Imunogeni pripravak u skladu s patentnim zahtjevom 3, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina € (MenC).
The cysteine-engineered anti-CD79b antibody of claim 6 wherein the antibody further comprises one or more of: 
Protutijelo anti-CD79b cisteinskog inženjeringa prema zahtjevu 6, naznačeno time, da protutijelo nadalje obuhvaća jednu ili više od sljedećih:
the amino acid sequence of SEQ ID NO:20 or an amino acid sequence at least 95% identical to SEQ ID NO: 20, and 
aminokiselinska sekvenca SEQ ID NO:20 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 20, i
an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA (dsRNA) duplex of a protein-binding segment, wherein the activator-RNA hybridizes with the targeter-RNA to form a total of 8 to 15 base pairs, 
segment koji se veže na proteine koji međudjeluje s navedenim polipeptidom Cas9, gdje segment koji se veže na proteine sadrži dva komplementarna odsječka nukleotida koji hibridiziraju kako bi tvorili dvolančani RNA (dsRNA) dupleks; i gdje
treating Compound 9 with a C1 to C6 alkyl carbonyl compound and a carbonate base in a biphasic solvent system to produce purified Compound 8; and 
[image] obradi Spoja 9 nižim alkilkarbonilnim spojem i karbonatnom bazom u dvofaznom sustavu otapala kako bi se dobilo pročišćeni Spoj 8;
resistively heating the core by supplying it with electric current to reduce the viscosity of the surrounding filler material; and 
(a) zagrijavanje jezgre (2) električnom strujom radi smanjivanja viskoznosti materijala za ispunu (7), koji se nalazi oko nje;
By sub-clinical progression is meant the development of the disease prior to the point at which the symptoms of the disease become apparent by clinical as opposed to biochemical investigation or investigation using scanning techniques such as computerised tomography or magnetic resonance imaging (MRI). 
Pod sub-kliničkom progresijom se podrazumijeva razvoj bolesti prije točke u kojoj simptomi bolesti postaju klinički očiti, a što je suprotno biokemijskom istraživanju ili istraživanju uporabom tehnika skeniranja poput kompjutorizirane tomografije ili magnetske rezonance (MR).
A pharmaceutical combination of Claim 25 wherein the anti-diabetic agent is selected from insulin secretagogues; insulin sensitizers; anti-hyperglycemic agents; biguanides; sulfonyl ureas; glucosidase inhibitors; aldose reductase inhibitors; PPAR Y agonists including thiazolidinediones; PPAR a agonists, including fibric acid derivatives; PPAR δ antagonists or agonists; PPAR a/Y dual agonists; 11-B-HSD-1 inhibitors; dipeptidyl peptidase IV inhibitors; SGLT2 inhibitors; glycogen phosphorylase inhibitors; meglitinides; insulin; glucagon-like peptide-1; glucagon-like peptide 1 agonists; and protein tyrosine phosphatase-1B inhibitors. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je sredstvo protiv dijabetesa odabrano od sredstava za lučenje inzulina, sredstava za osjet inzulina, sredstava protiv hiperglikemije, bigvanidina, sulfonil urea, inhibitora glukozidaze, inhibitora aldoza reduktaze, PPAR y agonista uključujući tiazolidindione, PPAR a agonista, uključujući derivate fibrinske kiseline, PPAR & antagonista ili agonista, PPAR a/y dvojnih agonista, 11-B-HSD-1 inhibitora, inhibitora dipeptidil peptidaze IV, SGLT2 inhibitora, inhibitora glikogen fosforilaze, meglitinida, inzulina, glukagon-sličnog peptida-1, agonista glukagon-sličnog peptida 1 i inhibitora protein tirozin fosfataze-1B.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
In particular is provided compounds of the invention which are dual inhibitors of the serotonin and noradrenaline transporters. 
Pogotovo se ovdje radi o spojevima izuma koji su dualni inhibitori transportera serotonina i noradrenalina.
Administration of the Compositions of the Present Invention 
Broj objave europskog patenta:
The compound according to claim 1 wherein R-A is selected from or 
Spoj prema patentnom zahtjevu 1 naznačen time što R-A je izabran od oo
The system (1) according to claim 3, characterized in that said control means (100) are adapted to: 
Sustav (1) u skladu s patentnim zahtjevom 3, naznačen time što je navedeni upravljački sklop (100) prilagođen za:
Compounds of formula (II) are known or may be obtained by known methods, e.g., as described in U.S. Pat. 
Spojevi formule (II) su poznati ili se mogu dobiti poznatim metodama, npr.
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula I or a pharmaceutically acceptable salt thereof, wherein: 
HR P20170183 T1 PATENTNI ZAHTJEVI Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule I R5
The antibody according to claim 13, wherein said contacting or said administrating is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
Antitijelo prema patentnom zahtjevu 13, naznačeno time, što se dovodi u kontakt odnosno primjenjuje na najmanje jedan od načina koji je izabran iz grupe koju čine parenteralna, potkožna, intramuskularna, intravenozna, intraartikularna, intrabronhijalna, intraabdominalna, intrakapsularna, intrahrskavična, intrakavitalna, intrakomorna, intracerebelarna, intracerebroventrikularna, intrakolična, intracervikalna, intragastrična, intrahepatična, intramiokardna, intraostealna, intrapelvična, intraperikardijalna, intraperitonealna, intrapleuralna, intraprostatična, intrapulmonalna, intrarektalna, intrarenalna, intraretinalna, intraspinalna, intrasinovijalna, intratorakalna, intrauterina, intravezikularna, intralezijska, bolusna, vaginalna, rektalna, bukalna, sublingvalna, intranazalna i transdermalna primjena.
Tapentadol according to any of the preceding claims, where dose c of tapentadol is administered during a third administration interval, following the second administration interval, where dose b < dose c. 
Tapentadol prema bilo kojem prethodnom patentnom zahtjevu, naznačen time da se doza c tapentadola daje tijekom trećeg intervala davanja, nakon drugog intervala davanja, gdje je doza b < doze c.
Preferentially, said incision line at the periphery of said central area of said first area comprises an initiating portion arranged for facilitating the initiation of said partly detachable packaging section, for example a more dense incision, an opening or a tab. 
Uzorak ambalažnog pakiranja u skladu sa zahtjevima 12 ili 13, naznačen time da navedena rezna linija na periferiji navedene središnje zone navedene prve zone (3) sadrži početni dio za olakšavanje započinjanja folije, na primjer gušći rez, otvor ili jezičac.
wherein R1, R2 and X are as defined in formula (1) and L is a leaving group such as halogen, provided that when R1 is benzyl, X is oxygen, R2 is methyl then L is not chlorine or when R1 is benzyl, X is a bond, R2 is propyl then L is not chlorine, represent a further aspect of the invention. 
(2a) naznačen time da R!, R*i X su kako je definirano u formuli (1) iz zahtjeva 1 i L je izlazna skupina, uz uvjet da kada R' je benzil, X je kisik, R? je metil tada L nije klor ili kada R! je benzil, X je veza, R? je propil tada L nije klor.
The composition according to claim 1, wherein the composition is a molding or coating composition. 
Spoj prema zahtjevu 9, naznačen time da spoj je spoj za premazivanje ili žbukanje.
Plasma glucose and hematocrit levels along with body weight are measured before the study began (day 0) and at the end of the study (day 14). 
Plazma glukoza i hematokrit razine, uz tjelesnu težinu, mjeri se prije početka ispitivanja (0. dan), te na kraju ispitivanja (14. dan).
The method of any one of Claims 1 to 23, further comprising cooling the soluble spray-dried composition from a heated temperature below the glass transition temperature. 
. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 23, koji se dodatno sastoji u hlađenju topivog pripravka osušenog raspršivanjem nakon grijanja na temperaturu ispod staklišta, t>&
calculating (76) the location and orientation of the IOL within the eye; and generating (78) a placement guide comprising an image that a surgeon may reference during IOL implantation surgery to position the incision and to properly center and orient the IOL. 
pribavljanje povratnih podataka kirurgu povezanih sa mjestom i orijentacijom IOL-a unutar oka; i uporaba navođenja položaja za provjeru (80) pozicioniranja IOL-a unutar oka.
The metal substrate of claim 8, wherein the electroplated metal layer is selected from the group consisting of nickel, nickel-phosphorus, copper, brass, gold, silver, and platinum. 
Metalna podloga u skladu s patentnim zahtjevom 8, naznačen time što se galvanizirani metalni sloj bira iz skupine koju čine nikal, niklo-fosfor, bakar, mjed, zlato, srebro, te platina.
wherein: • the body is a solid plasma crucible (11) of material which is lucent for exit of light therefrom, and 
tijelo je kruta plazmena retorta (11) tvari koja je prozirna tako da propušta svjetlo koje iz njega izlazi, i
reacting a compound of formula 3b under suitable oxime formation conditions to form the compound of formula 4-i: 
Boo ši reakcijom spoja formule 4-i: pod pogodnim uvjetima stvaranja klorooksima.
user receivers designed to be part of a user vehicle. 
- < sastavni dio korisnikovog vozila.
In the so defined range, particularly, thicknesses/gages between 5 mm and 120 mm have to be outlined. 
U tako definiranom području naročito trebaju biti obuhvaćene debljine/kalibri između 5 mm i 120 mm.
Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Spoj prema patentnom zahtjevu 11, naznačen time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića izazvan pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.
Recoil damper system according to claim 3, in which said guides (23) and said housings (24) are designed to work together in order to support and/or house the damping means (40). 
Sustav za prigušivanje trzanja u skladu s patentnim zahtjevom 3, u kojemu su navedene vodilice (23) i navedena kućišta (24) izvedeni tako da rade zajedno kako bi poduprli 1/1li smjestili sredstva za prigušivanje (40).
The process according to claim 6, wherein the intrinsic viscosity of the post-consumer polyester resin is higher than 0.6 ml/g, preferably higher than 0.65 ml/g, and the post-consumer resin is upgraded by means of reactive extrusion during the compounding process. 
Postupak prema patentnom zahtjevu 5, naznačen time da je intrinzična viskoznost post-potrošačke PET smole viša od 0.6 ml / g, poželjno viša od 0.65 mL / g, te se viskoznost post-potrošačke smole povećava pomoću produženog lanca, reaktivnih aditiva tijekom procesa miješanja.
According to another embodiment before or during or after steps c) and/or d) a dispersing agent is added. 
Postupak prema bilo kojem od zahtjeva 1 do 11, gdje se prije ili za vrijeme ili nakon koraka c) i/ili d) dodaje sredstvo za disperziju.
Permanent magnetic fields can be produced by using known composite magnetic materials. 
Permanentna magnetska polja mogu se proizvesti uporabom poznatih kompozitnih magnetskih materijala.